NGM BIOPHARMACEUTICALS INC
DelistedCIK 1426332fmd_0X6VH9P1K9FXJRARFXT9M81KBQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Dec 31, 2023, 25 periods
Latest annual · FY2023
Millions- Total revenues
- 4
- Operating income
- (151)
- Net income
- (142)
Latest quarter · Q4 FY2023
Millions- Total revenues
- 0
- Operating income
- (30)
- Net income
- (28)
Bulls and bears
Loading
News summary
An AI model writes the summary on request, from this company's recent filings only, and cites each filing it uses.
AI-written
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- -63.0%
- Revenue, 5 yearsFY2018 to FY2023
- -47.3%
- Net income, 5 yearsFY2018 to FY2023
- n/m
NGM BIOPHARMACEUTICALS INC financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $4.4 million | $55.3 million | -92% | 10-K 2024-03-11 · proof |
| Operating income | -$151.5 million | -$166.2 million | 10-K 2024-03-11 · proof | |
| Net income | -$142.4 million | -$162.7 million | 10-K 2024-03-11 · proof | |
| Cash from operating activities | -$132.2 million | -$144.4 million | 10-K 2024-03-11 · proof | |
| Total assets | $168.9 million | $307.4 million | -45.1% | 10-K 2024-03-11 · proof |
| Total liabilities | $20.2 million | $47.8 million | -57.7% | 10-K 2024-03-11 · proof |
| Cash and cash equivalents | $55.8 million | $73.5 million | -24% | 10-K 2024-03-11 · proof |
- What was NGM BIOPHARMACEUTICALS INC's revenue in fiscal 2023?
- NGM BIOPHARMACEUTICALS INC reported revenue of $4.4 million for fiscal 2023 (the year ended Dec 31, 2023), against $55.3 million the year before (-92%). Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What was NGM BIOPHARMACEUTICALS INC's operating income in fiscal 2023?
- NGM BIOPHARMACEUTICALS INC reported operating income of -$151.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$166.2 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What was NGM BIOPHARMACEUTICALS INC's net income in fiscal 2023?
- NGM BIOPHARMACEUTICALS INC reported net income of -$142.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$162.7 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What was NGM BIOPHARMACEUTICALS INC's cash from operating activities in fiscal 2023?
- NGM BIOPHARMACEUTICALS INC reported cash from operating activities of -$132.2 million for fiscal 2023 (the year ended Dec 31, 2023), against -$144.4 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What are NGM BIOPHARMACEUTICALS INC's total assets?
- As of Dec 31, 2023, NGM BIOPHARMACEUTICALS INC reported total assets of $168.9 million, against $307.4 million a year earlier (-45.1%). Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What are NGM BIOPHARMACEUTICALS INC's total liabilities?
- As of Dec 31, 2023, NGM BIOPHARMACEUTICALS INC reported total liabilities of $20.2 million, against $47.8 million a year earlier (-57.7%). Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
- What are NGM BIOPHARMACEUTICALS INC's cash and cash equivalents?
- As of Dec 31, 2023, NGM BIOPHARMACEUTICALS INC reported cash and cash equivalents of $55.8 million, against $73.5 million a year earlier (-24%). Source: the 10-K filed with the SEC on Mar 11, 2024. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1426332&period_type=annual&limit=5"Information only, not investment advice.